FOLD News and Press, Amicus Therapeutics Inc. From 10/13/19

On the good news front in today's series, Stealth BioTherapeutics ( MITO ) and Alexion Pharmaceuticals ( ALXN ) have agreed to co-develop and commercialize elamipretide for mitochondrial diseases. Elamipretide, an inner mitochondrial membrane-targeting therapeutic, is Stealth BioTherapeutics...

Amicus Therapeutics (NASDAQ: FOLD ) expects Galafold sales in Q3 to be ~$48M, up 133% from a year ago and above consensus of ~$45M. More news on: Amicus Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Analyst Day 2019 to Highlight Financial Outlook and Robust Portfolio of Novel Therapies for Rare Metabolic Diseases 3Q19 Galafold ® (migalastat) Preliminary Unaudited Revenue of ~$48M+   and 1,000+ Patients on Therapy Reflects Continued Strong Global Uptake ...

Shares of the rare disease specialist Amicus Therapeutics (NASDAQ: FOLD) fell by 18.9% last month, according to data from  S&P Global Market Intelligence . What's been weighing on this top orphan-drug stock? Amicus' stock has been imploding over the last two months due to the ...

The top-rated mid-cap sectors are financials (First Financial Bankshares ( FFIN ), LegacyTexas Financial ( LTXB ), Legg Mason ( LM ), Assured Guaranty ( AGO )), utilities (Ormat Technologies ( ORA ), Avista ( AVA )), industrials (Simpson Manufacturing ( SSD ), MasTec ( MTZ ), Trex Company ( TR...

Gainers:  electroCore (NASDAQ: ECOR ) +43% . Avaya Holdings (NYSE: AVYA ) +26% . RingCentral (NYSE: RNG ) +26% . Exela Technologies (NASDAQ: XELA ) +23% . YRC Worldwide (NASDAQ: YRCW ) +17% . Zosano Pharma Corporation (NASDAQ: ZSAN ) +16% . BroadVision (NASDAQ: BVSN ) +16% . Ch...

The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with this Read more ...

Amicus Therapeutics ( FOLD +6.5% ) rebounds on heavy volume a day after dropping to fresh two-year lows before ultimately netting a gain for the day. More news on: Amicus Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Persistent and Durable Responses Across Safety, Functional Outcomes and Biomarkers for ERT-Naïve and ERT-Switch Patients in Cohorts 1, 2 and 3 Out to Month 24 Data in Additional Switch Patients (Cohort 4) Consistent with Reponses in Previous Cohorts Demonstrating Improvements ...

CRANBURY, N.J., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following medical and investor conferences in October. Upcoming Medical Conferences: An oral presentation highlighting Phase 1/2 results, including coho...